KBC Securities - BIOTALYS NV (BTLS) Biotalys 1H25 underscores its prudent and cost-efficient operating strategy

Report

KBC Securities

Guy Sips

Biotalys 1H25 underscores its prudent and cost-efficient operating strategy

Biotalys' 1H25 financials, including a cash position of €15.7m at period-end, underscore its disciplined and cost-conscious strategy, providing a financial runway through May 2026. We maintain our Buy and € 6.1 Target Price.

18/09/2025 1 EN

Underlying

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Morning Notes : NEXTA BB, SOF BB, UCB BB, BTLS BB, ONWD BB, EXO NA

: NEXTA BB, SOF BB, UCB BB, BTLS BB, ONWD BB, EXO NA

September 18, 2025 September 18, 2025 1 EN

KBC Securities

Morning Notes : ACKB BB, HAL NA, NEXTA BB, RECT BB, RET BB, UCB BB, BTLS BB, ECMPA NA

: ACKB BB, HAL NA, NEXTA BB, RECT BB, RET BB, UCB BB, BTLS BB, ECMPA NA

August 29, 2025 August 29, 2025 1 EN

Morning Notes : FAGR BB, IVA FP, SOF BB, ENRGY BB

: FAGR BB, IVA FP, SOF BB, ENRGY BB

22h / 17m 22h / 17m 1 EN

Jacob Mekhael

Jacob Mekhael

Inventiva CMD outlines lanifibranor's differentiation in MASH

Yesterday, Inventiva hosted a CMD which highlighted the potential of lanifibranor in MASH. Our main takeaways are i) the number of diagnosed/treated MASH patients is on the rise, a trend that is expected to continue, ii) the future of the MASH landscape will involve combination therapies with GLP-1 likely being the backbone, and iii) lanifibranor is well positioned to reach a broader set of prescribers incl. endocrinologists thanks to its mechanism and metabolic benefits. We reiterate our € 8 TP and BUY.

22h / 51m 22h / 51m 1 EN

Wim Hoste

Wim Hoste

Titan Titan America receives qualification for lintel products

Titan America received Miami-Dade County's Notice of Acceptance for lintel products, which paves the way for Titan America to further extend its vertical integration into the lintel market. We remind that Titan recently reported resilient 1H25 results with EBITDA up 2% y/y, which was about 1% better than our forecast. We continue to remain optimistic on TITAN's prospects in the US and remind that only one third of Titan America's sales is imported in the US (with future tariff rate settled at 15%). Additionally, the US remains a net-import market in which c. 24% of consumption is imported, imp...

22h / 54m 22h / 54m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Biotalys 1H25 underscores its prudent and cost-efficient operating strategy

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : NEXTA BB, SOF BB, UCB BB, BTLS BB, ONWD BB, EXO NA

Morning Notes : ACKB BB, HAL NA, NEXTA BB, RECT BB, RET BB, UCB BB, BTLS BB, ECMPA NA

Morning Notes : FAGR BB, IVA FP, SOF BB, ENRGY BB

Inventiva CMD outlines lanifibranor's differentiation in MASH

Titan Titan America receives qualification for lintel products

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe